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Abstract
The effect of the immunomodulatory chemotherapeutic agent cyclophosphamide (CTX) on tumor growth was inves-
tigated in primary and metastatic intracerebral and subcutaneous rat xenograft models. Nude rats were treated with
CTX (100 mg/kg, intraperitoneally) 24 hours before human ovarian carcinoma (SKOV3), small cell lung carcinoma
(LX-1 SCLC), and glioma (UW28, U87MG, and U251) tumor cells were inoculated subcutaneously, intraperitoneally,
or in the right cerebral hemisphere or were infused into the right internal carotid artery. Tumor development was
monitored and recorded. Potential mechanisms were further investigated. Only animals that received both CTX
and Matrigel showed consistent growth of subcutaneous tumors. Cyclophosphamide pretreatment increased the
percentage (83.3% vs 0%) of animals showing intraperitoneal tumors. In intracerebral implantation tumor models,
CTX pretreatment increased the tumor volume and the percentage of animals showing tumors. Cyclophosphamide in-
creased lung carcinoma bone and facial metastases after intra-arterial injection, and 20% of animals showed brain
metastases. Cyclophosphamide transiently decreased nude rat white blood cell counts and glutathione concentration,
whereas serum vascular endothelial growth factorwas significantly elevated. Cyclophosphamide also increased CD31
reactivity, a marker of vascular endothelium, and macrophage (CD68-positive) infiltration into glioma cell–inoculated
rat brains. Cyclophosphamide may enhance primary and metastatic tumor growth through multiple mechanisms, in-
cluding immune modulation, decreased response to oxidative stress, increased tumor vascularization, and increased
macrophage infiltration. These findingsmay be clinically relevant because chemotherapymay predispose human can-
cer subjects to tumor growth in the brain or other tissues.
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Introduction
Metastatic spread, not primary tumor burden, is the leading cause of
cancer death. Animal models of human metastatic tumors are an im-
portant tool for evaluating potential therapies; however, for many
human tumor cells, xenografted human tumor growth in immuno-
deficient nude rats can be unsuccessful, inconsistent, or slow. This
effect is particularly problematic in brain tumor models, in which
tumor growth cannot easily or inexpensively be monitored externally.
Cancer treatments have well-known toxic adverse effects; however,
opposite effects that enhance malignancy or metastasis are not well
understood. Chemotherapy can increase tumor angiogenesis by mo-
bilizing endothelial precursor cells in the bone marrow to migrate to
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the tumor [1,2]. Cyclophosphamide (CTX, Cytoxan) is a common che-
motherapeutic agent that has immunomodulatory effects in addition to
its direct cytotoxic activity. In the clinic, secondary malignancies have
developed in some patients treated with CTX used alone or in associ-
ation with other antineoplastic drugs and/or modalities [3–6]. In this
report, secondary malignancies caused by CTX treatment were not ob-
served. However, CTX pretreatment supported metastasis formation,
which often is not observed in xenograft models [7,8].
Cyclophosphamide pretreatment has been used as a mechanism to
improve the anticancer efficacy of viral oncolytic gene therapy [9–11].
The authors attribute the increased efficacy to a reduction in the in-
nate immune response elicited by the virus that would normally re-
duce the quantity and spread of virus particles in the brain. It is
known that a single dose of CTX can decrease total splenocyte number
and CD4+25+ regulatory T cells [12–14]. Recently, Yamauchi et al. [15]
reported that CTX pretreatment induced human fibrosarcoma cancer
metastasis in a mouse model. In another mouse model, formation of
lung metastases was also enhanced up to 1000-fold by CTX pretreat-
ment [16]. In both studies, CTX (200 mg/kg, intraperitoneally (i.p.))
was given to the mouse 24 hours before tumor cell injection. Because
the half-life of CTX is approximately 17 minutes, the drug should not
affect the viability of tumor cells injected 24 hours later [17]. Nude (rnu/
rnu) rats lack a thymus butmaintain innate immune activities, including
natural killer cells. Similar to the mouse models, we hypothesized that
using CTX pretreatment (24 hours before tumor cell inoculation) to
reduce the innate immune response might improve the growth and/or
metastasis of human tumor xenograft models in nude rats.
Although CTX has known immunomodulatory effects, changes in
tumor growth may also be attributable to alternate mechanisms. Glu-
tathione (GSH) is a major endogenous antioxidant, with important
roles in detoxifying free radicals and reactive oxygen species [18]. De-
creased GSH and/or increased oxidative stress may impact expression
of vascular endothelial growth factor (VEGF), the major angiogenic
factor during epithelial carcinogenesis in a large number of human
cancers and metastases [19,20]. The growth of malignant tissues
and tumor metastases are dependent on adequate vascularization.
The objective of this study was to investigate if single-dose pretreat-
ment with the immunomodulatory chemotherapeutic agent CTX
improved tumor growth in subcutaneous, intracerebral, and meta-
static nude rat xenograft models. Our second goal was to investigate
potential mechanisms involved in this effect.
Materials and Methods
The care and use of the animals was approved by the institutional
animal care and use committee and was under the supervision of the
Department of Comparative Medicine at Oregon Health and Science
University. Female (200-250 g) nude (rnu/rnu) and heterozygous
(rnu/wt) rats were selected from the breeding colony maintained
in the animal facility at Oregon Health and Science University. All
animals were housed in individually hanging wire-bottom cages sup-
plied with an automated watering system in a room with a 12-hour
light-dark cycle maintained at 22 ± 2°C. Food and water were sup-
plied to all rats ad libitum. Cyclophosphamide powder was purchased
from Bristol-Myers Squibb Company (Princeton, NJ). The powder
was resuspended with sterile saline before use.
Rat Xenografted Tumor Models
Human cancer cell lines used in this study were human ovarian car-
cinoma (SKOV3), small cell lung carcinoma (LX-1 SCLC), and gli-
oma (UW28, U87MG, and U251). All cells were cultured with
proper medium supplemented with serum and antibiotics. SKOV3
and U87MG cells were obtained from the American Type Culture Col-
lection (Manassas, VA), UW28 and U251 human glioma cells were
obtained from Dr. Ali-Osman (Duke University), and LX-1 was origi-
nally obtained from Mason Research Institute (Worcester, MA). Cells
were harvested immediately before implantation and were used only if
viability exceeded 90%. Rats were pretreated with CTX (100 mg/kg,
i.p.) or saline 24 hours before tumor cell inoculation.
Subcutaneous tumor model. A total of 2.5 × 107 cells were mixed
(ratio, 1:1) with Matrigel Basement Membrane Matrix (BD Biosci-
ences, Bedford, MA), and the mixture was injected subcutaneously
into the left or right flank. Tumor growth was measured every 3 to
4 days using a dial caliper. The subcutaneous tumor volume was cal-
culated as follows: (tumor length)2 × tumor width/2. Animals were
killed at 35 days after tumor implantation.
Intraperitoneal tumor model. A total of 2.5 × 107 SKOV3 human
ovarian cells were injected into the peritoneal cavity. Animals were
monitored and killed at predetermined time points (8-12 weeks)
or when clinical symptoms indicated.
Intracerebral tumor model. Rats were anesthetized with ketamine
(60 mg/kg, i.p.) and diazepam (7.5 mg/kg, i.p.). Cells (106 in 12-15 μl)
were injected into the caudate nucleus in the right caudate putamen
(vertical, bregma — 6.5 mm; lateral, bregma — 3.1 mm) as previ-
ously described [21,22]. Intracerebral tumor growth was monitored
by magnetic resonance imaging (MRI) and histology.
Hematogenous metastasis model. Rats were anesthetized with iso-
f lurane (5% induction, 2% maintenance Aerrane; Anaquest, Inc.,
Madison, WI), and LX-1 SCLC cells (1-5 × 106 in 1 ml saline) were
infused retrograde into the right internal carotid artery as previously
described [21]. Systemic and intracerebral tumor growth was moni-
tored by MRI and histology.
Magnetic Resonance Imaging
Magnetic resonance imaging was performed on intracerebral and
hematogenous models at time points determined by prior studies
with the individual tumor types. Rats were anesthetized using i.p.
medetomidine (0.6 mg/kg Domitor; Orion Pharma, Espoo, Finland)
and ketamine (15 mg/kg) and were imaged on a 3-T MRI scanner
(Siemens Magnetom Trio, Erlangen, Germany) using a custom rat head
transmitter-receiver coil as previously described [22]. The 3-T imag-
ing sequences were as follows: T1-weighted spin echo with relaxation
time (TR) = 750 milliseconds and echo time (TE) = 12 milliseconds;
T2-weighted turbo spin echo (TR = 5430 milliseconds, TE = 78 milli-
seconds); and fluid-attenuated inversion recovery (TR = 9280 millisec-
onds, TE = 89 milliseconds, inversion time = 2100 milliseconds). The
voxel size was 0.26 × 0.26 × 2 mm for coronal scans. T1-weighted scans
were acquired before and after gadolinium (Omniscan; Amersham
Health AS, Oslo, Norway) at a dose of 0.1 to 0.3 mmol/kg injected into
a femoral vein. AfterMRI,medetomidine was reversed using atipamezole
(Antisedan; Orion Pharma, Espoo, Finland).
Histology and Immunohistochemistry
Animals were killed at predetermined time points or when clinical
symptoms indicated. Brains were excised and fixed in 10% buffered
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formalin for vibratome sectioning, 100 μm in the coronal plane. For
intracerebral tumor volumetrics, every sixth brain section was stained
with hematoxylin and then imaged at high resolution (30 μm pixel
diameter) on flatbed scanner (Expression 1640XL; Epson, Long
Beach, CA) using Adobe Photoshop software. Tumor volume was
assessed using NIH Image software. Immunohistochemistry was per-
formed by incubating the brain slices with proper dilutions (1:50 to
1:2000) of primary antibodies. Mouse antihuman nuclei monoclonal
antibody (clone 3E1.3) was purchased from Chemicon/Millipore
(Temecula, CA). Anti-CD31 (sc-46694), CD68 (sc-7084), and VEGF
(sc-1836) antibodies were purchased from Santa Cruz Biotechnology,
Inc. (Santa Cruz, CA). Then tissue slices were further incubated with
the appropriate biotinylated secondary antibody and visualized with
the Vectastain ABC kit (Vector Laboratories, Burlingame, CA) using
diaminobenzidine. A control for immunostaining omitted the primary
antibody to demonstrate diaminobenzidine reactivity. Images were ob-
tained with an Axiocam digital camera mounted on a Zeiss Axioplan
microscope (Carl Zeiss Co., Oberkochen, Germany).
Rat Hematology, GSH, and VEGF Measurements
For blood count analysis, rat whole blood (0.5 ml) was collected
in EDTA microtubes before treatment and at 1, 3, 7, and 14 days
after administration of CTX (100 mg/kg, i.p.). Blood counts were
analyzed in duplicate on a Hemavet 850 counter (CDC Technolo-
gies Inc., Oxford, CT). Rat serum was collected by centrifugation
(2000 rpm at 4°C) and stored at −20°C for future use.
Rat serum GSH content was measured using the Quantichrom GSH
assay (BioAssay Systems, Hayward, CA). Serum samples (250 μl of
1:5 dilution, in duplicate) were evaluated according to the manufac-
turer’s protocol. The GSH concentration was quantitated by compar-
ing the 405-nm optical density of the sample with a GSH standard.
Rat serum VEGF level was measured using the Quantikine sand-
wich ELISA kit (R&D Systems, Minneapolis, MA). Standard, con-
trol, and serum samples (50 μl each, in duplicate) were added to a
96-well plate precoated with a specific antibody against rat VEGF,
and the assay was performed as described by the manufacturer. The
serum VEGF concentration was quantitated by comparing the optical
density of the sample at 450 nm with a standard generated according
to the manufacturer’s instructions.
Statistical Analysis
The results were expressed as mean ± SEM, and the significance of
the difference between the mean values of the treated animals and
those of controls was determined by the Student’s t test. The level
of significance was corrected by multiplying the P value by the num-
ber of comparisons performed (n) according to Tukey’s correction.
The paired Student’s t test was used to compare the values of the
parameters before and after treatment. For data analysis, one-way
analysis of variance test was performed by comparing the different
arms of treatment of the single variables. Significance was determined
at the 5% level, two-sided.
Results
Cyclophosphamide Enhanced Subcutaneous and
Intraperitoneal Tumor Growth
To investigate the effect of CTX on subcutaneous tumor devel-
opment, we pretreated female nude rats with CTX (100 mg/kg, i.p.)
24 hours before the injection of tumor cells, with or without Matrigel,
into the left or right flank. Matrigel alone produced a subcutaneous
mass immediately after injection but reabsorbed and disappeared
within 3 days (the first day for tumor measurement). With the LX-1
human SCLC cells, small subcutaneous tumors that were often pal-
pable but not measurable grew in the absence of CTX or Matrigel,
with final volume of 1.5 ± 0.8 cm3 at 35 days (n = 5; Figure 1A).
Addition of either Matrigel or CTX moderately enhanced LX-1 sub-
cutaneous tumor growth (3.6 ± 1.7 and 3.6 ± 1.5 cm3 at 35 days,
respectively). The combination of CTX pretreatment and Matrigel
synergistically increased LX-1 subcutaneous tumor growth (10.1 ±
3.1 cm3; Figure 1, A and B and Table 1). Subcutaneous tumors in
the +CTX group showed increased surface vascularity (Figure 1B).
Without the addition of Matrigel, SKOV3 ovarian carcinoma cells
did not form subcutaneous tumors in nude rats (not shown). Cyclo-
phosphamide pretreatment in combination with Matrigel significantly
enhanced SKOV3 tumor growth compared with Matrigel alone (1.5 ±
0.5 vs 0.3 ± 0.1 cm3; Figure 1C and Table 1). Without CTX pre-
treatment, SKOV3 tumor appeared largely avascular; tumor vascular-
ization was prominent in the CTX pretreatment group (Figure 1D).
The decrease in tumor volume 7 to 14 days after tumor implantation
might indicate loss of effectiveness of CTX in this model.
Without CTX pretreatment, SKOV3 ovarian carcinoma cells did
not form intraperitoneal tumors in nude female rats. After CTX pre-
treatment, five of six rats (83.3%) developed multiple intraperitoneal
ovarian tumor nodules (Figure 1E and Table 1). Tumors were found
at the mesentery region along the basal stomach and duodenum area.
In omentum, multifocal areas of necrosis, inflammation, and irregu-
lar anaplastic cells were found, typical of tumor invasion (Figure 1F ).
These results suggest that CTX pretreatment enhanced both subcu-
taneous and intraperitoneal tumor growth.
Cyclophosphamide Enhanced Intracerebral Tumor Growth
and Hematogenous Metastases
Several human tumor cell lines consistently form intracerebral tu-
mors when implanted in the caudate nucleus in nude rat brain in the
absence of CTX (Table 1). LX-1 human SCLC intracerebral tumors
grow quickly and consistently [21], with a volume of 29.1 ± 4.1 mm
at 12 days after implantation (Table 1). In contrast, MC116 human
B-lymphoma cells show inconsistent intracerebral growth [22]. Pre-
treatment with CTX (100 mg/kg, i.p.) increased the percentage of
animals showing MC116 brain tumor and improved the consistency
of growth (Table 1).
We tested one glioma model, human UW28 cells, that rapidly
formed large tumors in nude rat brain without CTX pretreatment,
with a volume of 71.8 ± 23.2 mm3 (n = 6) at 3 weeks after implan-
tation (Table 1). Two other glioma models, U87MG and U251,
showed slow and inconsistent growth. Pretreatment with CTX re-
duced the time delay to tumor detection by MRI and increased
the percentage of animals showing tumors in both models. In the
U87MG intracerebral glioma model, in the absence of CTX pretreat-
ment, no tumor was detected until 6 to 8 weeks after implantation
by MRI using either T1-weighted sequences with gadolinium en-
hancement (Figure 2A, top images) or T2-weighted sequences (Fig-
ure 2B, left panel ). In CTX-treated rats, U87MG intracerebral tumors
could be detected by MRI as early as 2 weeks after implantation and
progressively developed through 8 weeks (Figure 2A, bottom images
and Figure 2B, right).
Representative histologic findings in the glioma models is shown
in Figure 2C . Upon sacrifice, most animals receiving U87MG cells
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without CTX pretreatment showed either no tumor (two of six ani-
mals) or small brain tumors (three of six animals), and only one rat
had a large tumor (Figure 2D and Table 1). A broad range of tumor
size was found in the CTX-treated animals, with a mean tumor vol-
ume of 79.8 ± 33.5 mm3 at 6 to 8 weeks after implantation, and all
animals showed tumor growth. Similar effects of CTX were observed
in the U251 glioma model (Figure 2, C and D, and Table 1). With-
out CTX pretreatment, only four of six rats showed brain tumor at 6
to 8 weeks after implantation, with a mean tumor volume of 4.7 ±
2.9 mm3. With CTX pretreatment, U251 glioma grew in 100% of
animals with a mean volume of 67.5 ± 33.9 mm3 (n = 5). Owing to
the small sample size of the groups (n = 5-6) and high variability, the
CTX effect was not significant in either the U87MG or the U251
groups; however, statistical significance (P = .0085) was found be-
tween no CTX and CTX-treated animals if both U87MG and
U251 models were combined.
Figure 1. Effect of cyclophosphamide pretreatment on the growth of subcutaneous and intraperitoneal tumors. Female nude rats were
pretreated with CTX (100 mg/kg, i.p.) or saline 24 hours before cell implantation. (A–D) Subcutaneous tumor growth after inoculation of
250 μl (2.5 × 107) of tumor cells mixed with 250 μl of Matrigel or saline was measured by a dial caliper twice per week. (A) LX-1 SCLC
subcutaneous tumor development (mean ± SEM tumor volume, n = 5). (B) Representative LX-1 SCLC subcutaneous tumors excised
from animals five weeks after inoculation, from the +/− Matrigel and +/− CTX groups. Bar, 1 cm. (C) SKOV3 ovarian carcinoma sub-
cutaneous tumor development (mean ± SEM tumor volume, n= 5). (D) Representative SKOV3 ovarian carcinoma subcutaneous tumors
excised from animals five weeks after inoculation from +/− CTX groups. Bar, 1 cm. (E–F) Intraperitoneal tumor growth after inoculation
of 250 μl (2.5 × 107) of SKOV3 ovarian tumor cells. (E) Representative SKOV3 ovarian intraperitoneal tumors nine weeks after inoculation
in a +CTX rat. Arrows indicate tumor. (F) Histologic micrograph of omentum from a CTX treated animal. Arrows indicate irregular an-
aplastic cells; N indicates multifocal areas of necrosis and inflammation. Original magnification, ×200.
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In humans, brain metastases of systemic tumors occur through a
complicated sequence of intravasation, tissue localization, extravasa-
tion, and growth that is not well understood. To mimic this process,
we injected LX-1 human SCLC cells into the right internal carotid ar-
tery in nude rats. Without CTX pretreatment, two of five rats (40%)
had bone and facial metastases within 4 to 8 weeks of tumor cell
inoculation; none showed brain metastases (Table 1). With CTX
pretreatment, 10 of 10 rats developed bone and facial metastases after
intra-arterial LX-1 cell injection. The MRI in Figure 3A shows a tu-
mor in the mandibular region and another in the dura extending
into the skull of one rat, although no tumors were found in brain
parenchyma. Two (20%) of the CTX-treated animals showed brain
metastases (Figure 3B and Table 1). Our data suggested that CTX
pretreatment increased the occurrence of metastatic tumor growth
from tumor cells circulating in the vasculature. The mechanisms in-
volved in the difference of CTX effect among bone, facial, and brain
metastases are unknown and need to be further investigated.
Mechanisms of CTX Enhancement of Tumor Growth
A single dose of CTX (100 mg/kg, i.p.) decreased nude rat total
white blood cell counts (45.9 ± 2.9% of baseline on day 1, 30.5 ±
6.3% on day 3), lymphocytes (46.4 ± 7.3% and 54.9 ± 8.9%), and
neutrophils (45.7 ± 3.4% and 22.5 ± 4.1%) (Figure 4A). Blood
counts rebounded at day 10 and were back to baseline at day 21.
Figure 2. Effect of cyclophosphamide on the growth of implanted intracerebral gliomamodels. Female nude ratswere pretreatedwith CTX
(100mg/kg, i.p.) or saline 24 hours before stereotactic implantation of 106 human U87MG or U251 glioma cells into the caudate nucleus in
the right cerebral hemisphere. (A) T1-weighted coronal scans with gadolinium contrast, from a rat without CTX (top) or with CTX pretreat-
ment (bottom). Magnetic resonance imaging was performed every 2 weeks after inoculation of U87MG cells. (B) T2-weighted axial scans
from the same animals at 8 weeks after tumor implantation. (C) Representative U87MG (left) and U251 (right) tumors in the−CTX (top) and
+CTX (bottom) treatment groups. Coronal 100-μm vibratome sections were stained with antihuman nuclei antibody with a hematoxylin
background. (D) Bar graph (mean ± SEM) of U87MG (left) and U251 (right) brain tumor volumes in rats pretreated with or without CTX
(n = 5-6 per group). Brains were harvested for tumor volumetrics at 8 weeks (U87MG) or at 8 to 12 weeks (U251) after cell implantation.
Table 1. Summary of Cyclophosphamide Pretreatment on Different Rat Tumor Models.
Tumor Model Cell Lines
(Timeline)
Treatment Animal with
Tumor (%)
Tumor Volume
Subcutaneous SCLC LX-1
(5 wk)
No additions 4/5 (80%) 1.5 ± 0.8 cm3
Matrigel 4/5 (80%) 3.6 ± 1.7 cm3
Cytoxan 5/5 (100%) 3.6 ± 1.5 cm3
Cytoxan +
Matrigel
5/5 (100%) 10.1 ± 3.1 cm3
Ovarian SKOV3
(5 wk)
No cytoxan 3/5 (60%) 0.3 ± 0.1 cm3
Cytoxan 5/5 (100%) 1.5 ± 0.5 cm3
Intraperitoneal Ovarian SKOV3
(9 wk)
No cytoxan 0/2 (0%) n.d.
Cytoxan 5/6 (83.3%) n.d.
Intracerebral Lymphoma MC116
(3-4 wk)
No cytoxan 16/19 (84.2%) 48.4 ± 66.2 mm3
Glioma U87
(8 wk)
Cytoxan 12/13 (92.3%) 33.0 ± 16.9 mm3
No cytoxan 5/8 (62.5%) 14.6 ± 13.1 mm3
Glioma U251
(8-12 wk)
Cytoxan 8/8 (100%) 79.8 ± 33.5 mm3
No cytoxan 8/12 (66.7%) 3.2 ± 1.6 mm3
Glioma UW28
(3 wk)
Cytoxan 8/8 (100%) 67.5 ± 33.9 mm3
No cytoxan 6/6 (100%) 71.8 ± 23.2 mm3
SCLC LX-1
(3 wk)
No cytoxan 8/8 (100%) 29.1 ± 4.1 mm3
Hematogenous SCLC LX-1
(6 wk)
No cytoxan Brain 0/5 (0%) n.d.
Other* 2/5 (20%) n.d.
Cytoxan Brain 2/10 (20%) n.d.
Other* 10/10 (100%) n.d.
n.d. indicates not determined; wk, week(s).
*Animals developed facial or/and bone malignancy other than CNS tumor after intracarotid tumor
cell injection.
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The lymphocytopenia noted at baseline is common in nude rats. With
CTX treatment, lymphocyte counts were further reduced and almost
undetectable in some rats. No effect of CTX on erythrocytes and
platelets was found.
Treatment with CTX elevated the serum VEGF level from a basal
level of 3.2 ± 1.3 pg/ml to 13.1 ± 2.3, 6.1 ± 0.9, and 37.3 ± 14.3 pg/ml
at days 1, 3, and 7, respectively (Figure 4B). Then serum VEGF level
returned to baseline at day 14 (3.1 ± 1.4 pg/ml). Owing to the small
Figure 3. Hematogenous metastases in nude rats. Female nude rats were pretreated with CTX (100 mg/kg, i.p.) or saline 24 hours before
infusion of 106 LX-1 human SCLC cells into the right internal carotid artery. (A) Gadolinium-enhanced T1-weighted MRI showing a man-
dibular tumor (lower arrow) and metastasis in the dura extending into the skull (upper arrow). (B) Histologic micrographs of LX-1 SCLC
brain metastases (arrows) in two CTX-pretreated rats. Arrows indicate tumor.
Figure 4. Effect of cyclophosphamide on nude rat blood counts, serum VEGF, and GSH levels. Female nude rats (n = 4-5) were treated
with CTX (100 mg/kg, i.p.). At the indicated time points, 0.5 to 1 ml of whole blood was collected, analyzed in duplicate on a Hemavet
850 counter for blood counts (A), and serum was assayed for VEGF (B) and GSH (C) levels using commercial kits as described in the
Materials and Methods section. For blood count analysis, data are presented as the percent of baseline counts (Day 0) for each animal
for total white blood cell, neutrophils, and lymphocytes. Significant differences from Day 0 are indicated by *(P < .05) and **(P < .01).
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sample size (n = 4-5) and individual variations, only the day 7 time
point was found to be significantly elevated from baseline (P =
.0066). At this same 7-day time point, serum GSH concentrations
were significantly reduced (39.0 ± 1.4 μM; P = .0112) compared
with other time points (56.3-58.3 μM; Figure 4C ). These results
suggest that a single dose of CTX might create an immune and an-
giogenic microenvironment suitable for tumorigenesis.
We hypothesized that transient suppression of host immune re-
sponses by CTX treatment could limit the infiltration of inflam-
matory cells into brain tissues. We further hypothesized that CTX
might transiently enhance intracerebral tumor growth in immune-
competent animals. To test these hypotheses, we evaluated for the
presence of tumor and inflammation at day 7 after intracerebral in-
oculation of U87MG human glioma cells in both nude rats and ge-
netically matched immune-competent heterozygous (rnu/wt) rats.
We found that CTX pretreatment actually enhanced the brain in-
flammation response as determined by a hyperintense T2-weighted
MRI signal in the inoculation area with gadolinium enhancement
on T1 weighted MRI scans (Figure 5, A and B). The volume of the
brain showing a signal change was larger in heterozygous rats (Fig-
ure 5B) than in nude rats (Figure 5A). Staining for CD31 (platelet
endothelial cell adhesion molecule, a marker of neovascularization)
was more intense and widespread in CTX-treated nude and heterozy-
gous rats compared with their untreated counterparts. Staining for
VEGF was higher in the CTX-treated rat brain but was not clearly
cell-associated. Immunohistochemistry for macrophages (CD68) was
elevated in the rat brains with CTX treatment (Figure 5A). Consistent
with our previous results, the intracerebral U87MG tumor volume
was larger in the CTX-treated nude rats than in the control rat even
at the very early stage (7 days; Figure 5B). Heterozygous rats showed
no tumor growth in the absence of CTX. Interestingly, CTX-treated
heterozygous rats did develop some tumor mass along the inoculation
track (Figure 5B). The presence of tumor cells was confirmed by stain-
ing for human nuclear antigen.
Discussion
For many human tumor cells, xenografted human tumor growth
in immunodeficient nude rats can be unsuccessful, inconsistent, or
slow. We hypothesized that impairment of the innate immune re-
sponse with systemic chemotherapy may increase the incidence and
growth of metastases in brain and other tissues.
We initially hypothesized that the tumor-enhancing effects of
CTX were due to the depletion of circulating white blood cells.
The time course of immune cell depletion in our study was similar
to that of previous studies in mice [23] and rats [24]. The cell type
specificity of the immunomodulation by CTX is unclear. Cyclophos-
phamide decreased mouse total splenocyte number by 50% within
3 to 4 days after treatment, particularly CD19+ splenocytes and
also decreased CD4+25+ regulatory T cells [12,13]. Alternatively,
CTX may decrease the numbers of CD8+ T cells while actually in-
creasing CD11b+ cells and CD44hi CD8+ memory lymphocytes [14].
Metronomic low-dose CTX selectively depleted regulatory T cells in
Figure 5. Effect of cyclophosphamide on immune cell infiltration in rat brain. Male nude rats (A) and immune-competent heterozygous rats
(B) were treated with saline (top panels) or CTX (100 mg/kg, i.p.; bottom panels) 24 hours before inoculation of U87MG human glioma cells
in the caudate nucleus in the right hemisphere. At 7 days after cell implantation, MRI was performed and brains were immediately as-
sessed for histology and immunocytochemistry. Images shown are T1-weighted MRI with gadolinium contrast (T1+Gd), hematoxylin his-
tology (hematox), CD31 (neovascularization), and CD68 (macrophage) immunohistochemistry. Arrows indicate tumor.
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cancer patients but also restored T and natural killer effector functions
[14,25]. Thus, it is clear that CTX can impact immune cells, although
the exact immunomodulatory effects are not completely elucidated.
Although immune cell depletion supports the hypothesis that
CTX acts by reducing innate immunity, the cell infiltration studies
in rat brain do not. We found that CTX pretreatment leads to a
widespread increase in MRI enhancement in the inoculated cerebral
hemisphere after tumor cell implantation. Immunostaining suggests
that this involves macrophage (CD68) infiltration into the brain.
Macrophages seem to be directly involved in tumor progression and
metastasis [26]. They may promote angiogenesis by producing angio-
genic growth factors, including VEGF, and proteinases such as matrix
metalloproteinase 9 [27]. Therefore, macrophages may both increase
vascularization and enhance tumor cell movement toward and intrava-
sation into more vessels. This places macrophages at the center of an
invasion microenvironment.
Vascular endothelial growth factor plays an important role in tumor
growth and metastasis, as an essential regulator of normal and abnor-
mal blood vessel growth. Our study showed that CTX treatment ele-
vated the VEGF concentration in normal rat serum by 11.6-fold at
1 week. Increased vascularization was seen on the surface of subcuta-
neous tumors (especially in SKOV3 ovarian tumor) in CTX-pretreated
animals. Immunostaining for CD31 and VEGF was elevated in the
rat brain at 7 days after the inoculation of human glioma in the
CTX treatment group. CD31 is a multifunctional molecule involved
in inflammation and vascular biology and is a marker for neovascular-
ization [28,29]. These observations led to the hypothesis that CTX
induces tumor growth secondary to modification of the vasculature
with VEGF. In support of this hypothesis, Park et al. [30] demon-
strated that CTX induced VEGF mRNA and protein expression in
rat thymus. In contrast, others have shown that CTX inhibited basic
fibroblast growth factor–stimulated neovascularization in the mouse,
suggesting that it acts as an antiangiogenic agent [31].
Cyclophosphamide has also been shown to mobilize myeloid-derived
suppressor and endothelial progenitor cells positive for CD34, CD133,
and VEGF receptor 2, which may be associated with increased levels
of VEGF [32]. The circulating endothelial progenitor cells are re-
cruited to tumor capillaries and obviously play an important role in
vascularization of malignant tumors for neo-angiogenesis [1,33]. Vas-
cular endothelial growth factor receptor 2 was found to mediate mac-
rophage infiltration into orthotopic pancreatic tumors in mice [34].
Similarly, we found increased macrophage infiltration into rat brain
in Figure 5A with CTX treatment. Others have shown a positive cor-
relation between circulating endothelial progenitor cell levels and tu-
mor volume found in mouse models [35–37]. Other studies suggest
that CTX may enhance metastasis due to vascular endothelial cell in-
jury [38,39] or inhibition of a host-based cancer-killing process [15].
The mobilization of progenitor cells by CTX may attribute additional
or alternative mechanisms involved in enhancement of tumor growth
and metastasis.
Glutathione is an endogenous antioxidant involved in multiple cel-
lular detoxification activities. Decreased GSH synthesis may be a re-
sponse to CTX-induced oxidative stress [40]. Cyclophosphamide has
been reported to increase [41,42] and decrease [43] GSH levels in
various animal models, but the effect is variable depending on the
tissue and time point tested. In patients with chronic lymphocytic
leukemia, CTX caused a decrease in serum and lymphocyte GSH
concentrations [44,45]. Impaired free radical scavenging activity in
response to CTX may favor tumor growth [18].
Secondary malignancies caused by CTX have not been observed
in our animal xenograft models but are seen infrequently in humans
[3–6]. We suggest that in our studies, CTX did not cause new tumor
neoplastic transformation but rather induced conditions that allowed
the local and/or distant outgrowth of existing tumor cells in both
CNS and non-CNS sites. In support of this, we found that CTX
pretreatment increased the occurrence of brain metastasis from 0%
to 20% and facial/bone metastasis from 20% to 100% in our LX-1
SCLC hematogenous model. Thus, in addition to promoting local
tumor growth, CTX pretreatment supports metastasis formation,
which is often not observed in xenograft models [7,8]. Together,
our results indicate that CTX may enhance primary and metastatic
tumor growth through multiple mechanisms. Lymphodepletion, de-
creased GSH, elevated VEGF, increased CD31-positive brain immu-
noreactivity, and macrophage infiltration after CTX treatment may
provide the environment for increased brain and/or other tissue tu-
mor growth.
A significant question is whether CTX can promote tumor growth
and/or CNS metastasis in humans. The active metabolite of CTX
has limited permeability across the blood-brain barrier and is unlikely
to affect micrometastases within the sanctuary of the CNS [46].
The unexpected tumor growth– and metastasis-enhancing effect of
CTX should be taken into consideration when deciding which cyto-
toxic chemotherapy treatment will be selected and applied to can-
cer patients.
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